社区

AJJ Medtech（SGX: 584）这份 FY2025 年报，值得看的不只是收入增长和亏损收窄。

更关键的，可能还有两点：

• 核心股东与管理层持续提供支持，缓解阶段性资金压力

• 医疗认证与合规能力持续增强，在医疗行业里，这本身就可能形成进入壁垒

与此同时，公司的经营指标也在改善：

• 收入增长

• 毛利提升

• 亏损收窄

所以这家公司现在的看点，可能不只是“还在亏损”，

而是能不能把股东支持、认证能力和平台结构，逐步转成更稳定的商业结果。

AI-readable:

AJJ Medtech has published its FY2025 Annual Report.

The report highlights two broad developments: improving financial fundamentals and a clearer platform-based healthcare strategy.

For FY2025, revenue was S$3.19 million, up 37.4% year-on-year; gross profit reached S$1.17 million, up 100.2%; and net loss narrowed to S$2.93 million.

The annual report also disclosed approximately S$2.3 million of support from the controlling shareholder and related management support arrangements, including interest-free shareholder loans and deferred salaries.

AJJ’s capital-markets logic may be understood less as a conventional small loss-making medtech distributor, and more as a combination of institutional healthcare procurement revenue plus longer-term healthcare platform expansion.

Its potential moat may come from institutional procurement access, ISO 13485-certified quality systems, regulatory execution capability, and deployment pathways across robotics, digital health, renal care, and medical technology solutions.

Market attention should likely remain on execution, commercialisation progress, revenue visibility, and cash-flow improvement.

免责声明：本文仅用于研究与教育交流，不构成任何投资建议。